

August 3, 2021

# Whys & hows of DOIs for grants

**Kristen Mueller**  
Senior Director, Scientific Program  
Melanoma Research Alliance

# About MRA

- Founded in 2007
- **Mission:** to end suffering and death due to melanoma by collaborating with all stakeholders to accelerate powerful research, advance cures for all patients, and prevent more melanomas.
- Largest non-profit funder of melanoma research in the world, granting \$131 million to 380 research projects at 152 different institutions across 19 countries.

# 100%

of donations to MRA go directly to our research program, without admin or overhead.  
[CureMelanoma.org](http://CureMelanoma.org)

# Why DOIs?

Adopting Persistent object Identifiers (PIDs), like DOIs and ORCID iDs, is critically important to the funding community, and the research community more broadly

- Reduces the administrative burden on applicants and awardees (applications, progress reports);
- Increase the transparency and discoverability of MRA's research grants;
- Make research outcomes from MRA grants accurately identifiable; and
- Allow MRA to capture more complete, timely, and accurate data to inform our scientific strategy and report MRA-funded advancements to our key stakeholders.

# DOIs In Proposal Central

- Back To Manage Awards
- Award Details
- Deliverables
- Budget
- Payments
- Correspondence - Notes
- Contacts
- Outcomes
- Outputs
- Abstract - Keywords
- Application - Review Information
- Research Subjects - Assurance
- Fundraising Development Resources
- Grant Donors

PI	Ariyan, Charlotte	Award ID	884686
Institution	Memorial Sloan-Kettering Cancer Center	Program	Team Science Award
Award Amount	\$300,000.00	Project Title	In-transit Melanoma Consortium
Award Start - Award End	5/4/2021 - 11/3/2022		<div style="width: 16%; background-color: green;">16%</div>
Expenditures	\$0.00		<div style="width: 0%; background-color: gray;">0%</div>
Paid (Less Refunds)	\$60,000.00		<div style="width: 20%; background-color: yellow;">20%</div>
Expenditures Less Paid	(\$60,000.00)		<div style="width: -100%; background-color: red;">-100%</div>

### Modify Award Details


PI	Ariyan, Charlotte	<a href="#">Change PI</a>	
Project Title	(TSA) In-transit Melanoma Consortium	<a href="#">Change Project Title</a>	
Institution	Memorial Sloan-Kettering Cancer Center	<a href="#">Change Institution</a>	
Award ID	<input type="text" value="884686"/>	Cycle	<input type="text"/>
Proposal Status	<input type="text" value="Awarded"/> <a href="#">Audit Trail</a>	Award Status	<input type="text" value="Active"/> <a href="#">Audit Trail</a>
Award Amount	<input type="text" value="\$300,000.00"/> <a href="#">Audit Trail</a>	<a href="#">Modify Award Period Dates and No Cost Extension</a>	
Start Date	<input type="text" value="5/4/2021"/>	End Date	<input type="text" value="11/3/2022"/>
Commitment Date	<input type="text" value="mm/dd/yyyy"/> <a href="#">Audit Trail</a>	Modified Commitment Date	<input type="text" value="mm/dd/yyyy"/> <a href="#">Audit Trail</a>

### Deliverable(s) Average Score

Add ORCID Funding Record

Register Crossref DOI

### Linked Applications & Awards



# DOIs In Proposal Central

- Back To Manage Awards
- Award Details
- Deliverables
- Budget
- Payments
- Correspondence - Notes
- Contacts
- Outcomes
- Outputs
- Abstract - Keywords
- Application - Review Information
- Research Subjects - Assurance
- Fundraising Development Resources
- Grant Donors

PI	de Lange, Titia	Award ID	577521
Institution	The Rockefeller University-Office of Development	Program	Team Science Award in Acral Melanoma
Award Amount	\$900,000.00	Project Title	Telomere crisis in acral melanoma: diagnostic and prognostic potentials
Award Start - Award End	6/1/2018 - 5/31/2022		79%
Expenditures	\$0.00		0%
Paid (Less Refunds)	\$900,000.00		100%
Expenditures Less Paid	(\$900,000.00)		-100%





### Modify Award Details

PI	de Lange, Titia	Change PI			
Project Title	(ACR TSA) Telomere crisis in acral melanoma: diagnostic and prognostic potentials	Change Project Title			
Institution	The Rockefeller University-Office of Development	Change Institution			
Award ID	577521	Cycle	2018		
Proposal Status	Awarded	Audit Trail	Award Status	Active	Audit Trail
Award Amount	\$900,000.00	Audit Trail	Modify Award Period Dates and No Cost Extension		
Start Date	6/1/2018	End Date	5/31/2022	No Cost Extension granted	
Commitment Date	mm/dd/yyyy	Audit Trail	Modified Commitment Date	mm/dd/yyyy	Audit Trail
Deliverable(s) Average Score		Crossref DOI	<a href="https://doi.org/10.48050/pc.gr.80549">https://doi.org/10.48050/pc.gr.80549</a>	Status: Update-Success	1/29/2021 10:13:00 AM
<input type="button" value="Save"/>	<input type="button" value="Cancel"/>	<input type="checkbox"/>	Add ORCID Funding Record		
<input type="checkbox"/> Update Crossref DOI					

# DOIs In Proposal Central

## Award Details



Grant ID	577521  <a href="https://doi.org/10.48050/pc.gr.80549">https://doi.org/10.48050/pc.gr.80549</a>	Project Title	Telomere crisis in acral melanoma: diagnostic and prognostic potentials
Award Amount	\$900,000.00	Primary Organization	The Rockefeller University-Office of Development
Award Start Date	06/01/2018	Award End Date	05/31/2022
PI and PI Equivalents	Titia de Lange (PI)  <a href="https://orcid.org/0000-0002-9267-367X">https://orcid.org/0000-0002-9267-367X</a>	Key Personnel	Dr. John H Petrini (*Mentor) John Maciejowski (*Young Investigator/Co-investigator)  <a href="https://orcid.org/0000-0001-8134-9308">https://orcid.org/0000-0001-8134-9308</a> Marcin Imielinski (*PI)  <a href="https://orcid.org/0000-0002-2211-4741">https://orcid.org/0000-0002-2211-4741</a>

### Lay Summary

Acral melanoma is a life-threatening disease with a poor prognosis. Unlike cutaneous melanoma, which is caused by UV damage to the DNA, the origin of acral melanoma is poorly understood. Recent analysis of the DNA sequence of these cancers has shown a great number of so-called rearrangements in their chromosomes but how these genomic changes occur is not known. Our aim is to determine whether the acral melanoma chromosomes are remodeled by telomere crisis. Telomere crisis is a stage of genome instability due to the loss of the protective telomeric elements at the ends of chromosomes. Without telomere protection, chromosome ends stick together, creating an unstable genome. The telomeric DNA withers away during the many cell divisions involved in cancer development. Once the telomeres become too short, cells experience extensive damage in their genome. Eventually, the telomeres are healed when cells activate telomerase, the enzyme that can re-synthesize the telomeric DNA. Acral melanoma genomes show evidence of the type of changes that are known to result from telomere crisis and often have altered a key gene needed for telomerase activity. Our team has extensive experience in studying telomere function, telomere crisis, and genomic alterations. We will use our expertise to determine whether and how telomere crisis shapes the melanoma genome. The objective is to develop tools to predict the prognosis and treatment response of individual acral melanomas.

## Cost

\$2/grant (current year + 2 years into the past)

\$0.50/grant for historical records

So, MRA registered it's ~340 awards for <\$500

# DOIs In Print

personnel (including for serving as an editor) from Elsevier outside the submitted work. Dr Teer reported receiving grants from the Melanoma Research Foundation and the National Cancer Institute (P30-CA76292) during the conduct of the study; in addition, Dr Teer had a patent pending for Negative Storage Model for genomic information. Dr Koomen reported receiving grants from the National Cancer Institute (CCSG P30-CA076292) during the conduct of the study. Drs Karreth and Messina reported receiving grants from the Melanoma Research Alliance during the conduct of the study. No other disclosures were reported.

**Funding/Support:** This work was supported by a Team Science grant from the Melanoma Research Alliance (<https://doi.org/10.48050/pc.gr.80550>). The work was also supported in part by the Molecular Genomics Core Facility, the Tissue Core Facility, and the Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer

3. Newell F, Wilmot EC, Sandstrom A, et al. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. *Nat Commun*. 2020;11(1):5259. doi:10.1038/s41467-020-18988-3

4. Yeh I, Jorgenson E, Shen L, et al. Targeted genomic profiling of acral melanoma. *J Natl Cancer Inst*. 2019;111(10):1068-1077. doi:10.1093/jnci/djz005

5. Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. *J Invest Dermatol*. 2007;127(1):179-182. doi:10.1038/sj.jid.5700490

6. Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. *Arch Dermatol*. 2003;139(3):282-288. doi:10.1001/archderm.139.3.282

*Bioinformatics*. 2005;23(14):1734-1736. doi:10.1093/bioinformatics/btp324

13. Teer JK, Zhang Y, Chen L, et al. Evaluating somatic tumor mutation detection without matched normal samples. *Hum Genomics*. 2017;11(1):22. doi:10.1186/s40246-017-0118-2

14. Sarcar B, Gimbrone NT, Wright G, et al. Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model. *FEBS Open Bio*. 2019;9(10):1689-1704. doi:10.1002/2211-5463.12702

15. Moon KR, Choi YD, Kim JM, et al. Genetic alterations in primary acral melanoma and acral melanocytic nevus in Korea: common mutated genes show distinct cytomorphological features. *J Invest Dermatol*. 2018;138(4):933-945. doi:10.1016/j.jid.2017.11.017

# DOIs In Award Letters

## Publications and Publicity.

(A) Publication: MRA anticipates that all scientifically significant results of the Research Proposal, whether negative or positive, will be published or otherwise publicly presented. Any publication based on or developed under the Award must, unless otherwise requested by MRA:

- i. Contain an acknowledgment in the following or similar language that includes the Award digital object identified (DOI): “This publication is based on research supported by the Melanoma Research Alliance award <https://doi.org/10.48050/pc.gr.143721>.” Recipients must also acknowledge “Melanoma Research Alliance” as a funding source in presentations reporting on research supported by the Award.

***We also emailed all of our Awardees to inform them of their DOI and how to use – I am happy to share template language upon request***